Compare PLMR & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLMR | PBLS |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2019 | 2026 |
| Metric | PLMR | PBLS |
|---|---|---|
| Price | $123.04 | $32.57 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $153.60 | N/A |
| AVG Volume (30 Days) | 180.6K | ★ 704.8K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.04 | N/A |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $875,967,000.00 | N/A |
| Revenue This Year | $192.25 | N/A |
| Revenue Next Year | $19.34 | N/A |
| P/E Ratio | $35.36 | ★ N/A |
| Revenue Growth | ★ 58.16 | N/A |
| 52 Week Low | $100.81 | $25.56 |
| 52 Week High | $147.62 | $42.49 |
| Indicator | PLMR | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 33.96 | 39.32 |
| Support Level | $116.69 | $26.42 |
| Resistance Level | $125.81 | $33.65 |
| Average True Range (ATR) | 4.01 | 3.14 |
| MACD | -1.55 | -0.93 |
| Stochastic Oscillator | 9.84 | 21.56 |
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. It provides insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The company's Earthquake product generate high premium.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.